(Q33809548)

29 July 2017

1 reference

title

Effects of interferon therapy in "non responder" patients with chronic hepatitis C. (English)

1 reference

29 July 2017

1 reference

1

Poynard T

1 reference

29 July 2017

Moussali J

2

1 reference

29 July 2017

Ratziu V

series ordinal

3

1 reference

29 July 2017

Regimbeau C

series ordinal

4

1 reference

29 July 2017

Opolon P

series ordinal

5

1 reference

29 July 2017

1 January 1999

1 reference

29 July 2017

Journal of Hepatology

1 reference

29 July 2017

31 Suppl 1

1 reference

29 July 2017

178-183

1 reference

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Actions of cytokines on the immune response and viral interactions: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Hepatitis C: somber views of natural history and optimistic views of interferon treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Trends in primary liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Interferon treatment of chronic hepatitis C with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Interferon treatment of cirrhotic patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Methods for combining randomized clinical trials: strengths and limitations.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980397-3

7 January 2021

10.1016/S0168-8278(99)80397-3

Identifiers

DOI

1 reference

29 July 2017

1 reference